Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
BDRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BDRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001643918 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials
No annual revenue filed since the period ending 2023-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Group's ability to continue as a going concern." | 20-F 2026-03-27 |
| Cash and burn | $11.3M cash; operating cash flow -$1.8M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-07-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PKF Littlejohn LLP, London, United Kingdom | PCAOB Form AP 2026-04-15 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$8.4M | -$7.4M | $11.3M | $81K | Needs four quarters | 20-F 2026-03-27 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 333-279994 | 424B3 | 2026-10-14 |
| Latest annual report | 20-F | 2026-03-27 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 732 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.2% |
| 1 month | -14.3% |
| 3 months | -80.8% |
| Year to date | -97.4% |
| 1 year | -98.8% |
| From 52-week high | -99.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| MTNB | Matinas Biopharma Holdings Inc. | $0.9270 | +3.00% | $908K |
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| SPRC | SciSparc Ltd. | $0.3307 | -10.62% | $815K |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier